Results 81 to 90 of about 161,997 (305)

Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib. [PDF]

, 2018
BackgroundEarly detection of adverse effects of novel therapies and understanding of their mechanisms could improve the safety and efficiency of drug development.
DeLisle, Robert K, Ganz, Peter, Hyde, Craig, Malarstig, Anders, Murthy, Ashwin C, Ostroff, Rachel, Segal, Mark R, Weiss, Sophie J, Williams, Stephen A   +8 more
core   +2 more sources

Multivariate linear regression to predict association of non‐invasive arterial stiffness with cardiovascular events

ESC Heart Failure, Volume 12, Issue 2, Page 1141-1150, April 2025.
Abstract Background Arterial stiffness is a crucial factor in determining an increase in systolic blood pressure and pulse pressure and can also predict the development of cardiovascular disease (CVD). The purpose of this study was to examine the relationship between arterial stiffness and future CVD.
Susan Darroudi, Mostafa Eslamiyeh, Amin Mansoori, Eisa Nazar, Maryam Alinezhad‐Namaghi, Reza Rezvani, Majid Ghayour‐Mobarhan, Habibollah Esmaily, Mohsen Moohebati, Gordon A. Ferns, Mark Ghamsary   +10 more
wiley   +1 more source

The potential of ACTH in the genesis of primary aldosteronism.

Frontiers in Endocrinology, 2016
Aldosterone is a homeostatic hormone, rising in volume depletion, sodium deficiency and potassium loading, in response to angiotensin11 and elevation of plasma potassium.
John Watson Funder, John Watson Funder
doaj   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Role of the Renin-Angiotensin System and Aldosterone on Cardiometabolic Syndrome

International Journal of Hypertension, 2011
Aldosterone facilitates cardiovascular damage by increasing blood pressure and through different mechanisms that are independent of its effects on blood pressure.
P. Stiefel, A. J. Vallejo-Vaz, S. García Morillo, J. Villar   +3 more
doaj   +1 more source

Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High‐Risk Vascular Disease: Insights From the ACCELERATE Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background The failure of cholesteryl ester transfer protein inhibitor torcetrapib was associated with an off‐target increase in plasma aldosterone. We sought to evaluate the impact of evacetrapib on plasma aldosterone level and determine the association
Anirudh Kumar, Divyang R. Patel, Danielle M. Brennan, Kathy E. Wolski, A. Michael Lincoff, Giacomo Ruotolo, Ellen McErlean, Govinda Weerakkody, Jeffrey S. Riesmeyer, Stephen J. Nicholls, Steven E. Nissen, Venu Menon   +11 more
doaj   +1 more source

The Postural Tachycardia Syndrome (POTS): Pathophysiology, Diagnosis & Management [PDF]

, 2006
Postural tachycardia syndrome (POTS), characterized by orthostatic tachycardia in the absence of orthostatic hypotension, has been the focus of increasing clinical interest over the last 15 years 1. Patients with POTS complain of symptoms of tachycardia,
Raj, Satish R
core   +1 more source

The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome [PDF]

, 2019
When hypertension, a pathology that is frequently found in the general population, presents in a young patient, secondary causes such as Cushing's syndrome (CS), a rare disease characterized by long-term elevated cortisol levels, should be considered ...
Barbot, Mattia, Ceccato, Filippo, Scaroni, Carla   +2 more
core   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances?

The Journal of Clinical Hypertension
The obesity pandemic, with its associated comorbidities of hypertension and diabetes, constitutes a global public health issue. Importantly, there is an increasing prevalence of aldosterone excess related to obesity and resultant poor health outcomes ...
Houry Puzantian, Raymond Townsend, Shweta Bansal   +2 more
doaj   +1 more source